TD Asset Management Inc. grew its stake in Enanta Pharmaceuticals Inc (NASDAQ:ENTA) by 10.5% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 35,148 shares of the biotechnology company’s stock after acquiring an additional 3,331 shares during the quarter. TD Asset Management Inc.’s holdings in Enanta Pharmaceuticals were worth $3,357,000 at the end of the most recent quarter.

Other institutional investors also recently added to or reduced their stakes in the company. Janus Henderson Group PLC raised its stake in shares of Enanta Pharmaceuticals by 17.0% in the first quarter. Janus Henderson Group PLC now owns 874,397 shares of the biotechnology company’s stock worth $83,522,000 after purchasing an additional 126,804 shares during the last quarter. Dimensional Fund Advisors LP raised its stake in shares of Enanta Pharmaceuticals by 3.2% in the fourth quarter. Dimensional Fund Advisors LP now owns 623,630 shares of the biotechnology company’s stock worth $44,172,000 after purchasing an additional 19,624 shares during the last quarter. Krensavage Asset Management LLC raised its stake in shares of Enanta Pharmaceuticals by 4.8% in the fourth quarter. Krensavage Asset Management LLC now owns 535,877 shares of the biotechnology company’s stock worth $44,071,000 after purchasing an additional 24,691 shares during the last quarter. Northern Trust Corp raised its stake in shares of Enanta Pharmaceuticals by 4.0% in the fourth quarter. Northern Trust Corp now owns 240,803 shares of the biotechnology company’s stock worth $17,055,000 after purchasing an additional 9,207 shares during the last quarter. Finally, Geode Capital Management LLC raised its stake in shares of Enanta Pharmaceuticals by 9.2% in the fourth quarter. Geode Capital Management LLC now owns 198,702 shares of the biotechnology company’s stock worth $14,073,000 after purchasing an additional 16,732 shares during the last quarter. 89.64% of the stock is currently owned by institutional investors and hedge funds.

Several research analysts have recently weighed in on ENTA shares. Berenberg Bank upgraded Enanta Pharmaceuticals from a “hold” rating to a “buy” rating and boosted their price target for the stock from $80.00 to $120.00 in a research note on Tuesday, April 23rd. BidaskClub cut Enanta Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, May 1st. Zacks Investment Research upgraded Enanta Pharmaceuticals from a “hold” rating to a “buy” rating and set a $99.00 price target for the company in a research note on Friday, May 10th. Finally, Wolfe Research started coverage on Enanta Pharmaceuticals in a research note on Friday, May 24th. They issued an “outperform” rating and a $117.00 price target for the company. Two equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $114.83.

Enanta Pharmaceuticals stock opened at $90.47 on Friday. The firm has a market cap of $1.80 billion, a P/E ratio of 24.55 and a beta of 1.30. Enanta Pharmaceuticals Inc has a one year low of $64.08 and a one year high of $127.77.

Enanta Pharmaceuticals (NASDAQ:ENTA) last posted its quarterly earnings data on Tuesday, May 7th. The biotechnology company reported $0.20 EPS for the quarter, beating analysts’ consensus estimates of ($0.09) by $0.29. The company had revenue of $39.60 million during the quarter, compared to analysts’ expectations of $40.92 million. Enanta Pharmaceuticals had a return on equity of 19.25% and a net margin of 33.28%. Enanta Pharmaceuticals’s revenue for the quarter was down 10.0% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.61 earnings per share. As a group, equities analysts forecast that Enanta Pharmaceuticals Inc will post 1.9 EPS for the current year.

In related news, Director George Golumbeski sold 9,280 shares of the company’s stock in a transaction on Monday, March 4th. The stock was sold at an average price of $103.65, for a total transaction of $961,872.00. Following the completion of the sale, the director now owns 9,280 shares in the company, valued at $961,872. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Bruce L. A. Carter sold 1,546 shares of the company’s stock in a transaction on Monday, March 11th. The shares were sold at an average price of $99.16, for a total value of $153,301.36. Following the sale, the director now owns 1,546 shares of the company’s stock, valued at approximately $153,301.36. The disclosure for this sale can be found here. 11.35% of the stock is currently owned by corporate insiders.

ILLEGAL ACTIVITY WARNING: “TD Asset Management Inc. Has $3.36 Million Holdings in Enanta Pharmaceuticals Inc (ENTA)” was first posted by Watch List News and is the sole property of of Watch List News. If you are viewing this piece on another website, it was illegally copied and reposted in violation of US and international copyright & trademark legislation. The correct version of this piece can be accessed at https://www.watchlistnews.com/td-asset-management-inc-has-3-36-million-holdings-in-enanta-pharmaceuticals-inc-enta/3029320.html.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc, a biotechnology company, focuses on the research and development of small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, non-alcoholic steatohepatitis, primary biliary cholangitis, and hepatitis B virus.

See Also: Strike Price

Want to see what other hedge funds are holding ENTA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Enanta Pharmaceuticals Inc (NASDAQ:ENTA).

Institutional Ownership by Quarter for Enanta Pharmaceuticals (NASDAQ:ENTA)

Receive News & Ratings for Enanta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.